Maxim Group set a $4.00 price target on Vistagen Therapeutics (NASDAQ:VTGN) in a research note published on Tuesday, October 15th, TipRanks reports. The firm currently has a buy rating on the stock.
Several other equities research analysts also recently weighed in on the company. ValuEngine upgraded Vistagen Therapeutics from a hold rating to a buy rating in a report on Thursday, August 1st. Chardan Capital reiterated a neutral rating on shares of Vistagen Therapeutics in a report on Monday, July 29th. Finally, William Blair reiterated a buy rating on shares of Vistagen Therapeutics in a report on Wednesday, October 9th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Vistagen Therapeutics presently has an average rating of Buy and an average price target of $2.35.
Vistagen Therapeutics stock traded up $0.07 during mid-day trading on Tuesday, reaching $1.08. 296,700 shares of the stock traded hands, compared to its average volume of 316,562. Vistagen Therapeutics has a 12-month low of $0.38 and a 12-month high of $2.06. The company has a debt-to-equity ratio of 2.44, a current ratio of 2.65 and a quick ratio of 2.65. The business’s 50-day moving average is $1.15 and its 200-day moving average is $0.83. The stock has a market capitalization of $46.20 million, a PE ratio of -1.20 and a beta of -0.29.
Vistagen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. Equities analysts anticipate that Vistagen Therapeutics will post -0.45 EPS for the current fiscal year.
A number of large investors have recently made changes to their positions in VTGN. LPL Financial LLC bought a new stake in Vistagen Therapeutics during the 2nd quarter valued at $27,000. Wells Fargo & Company MN bought a new stake in Vistagen Therapeutics during the 2nd quarter valued at $31,000. HighTower Advisors LLC boosted its position in Vistagen Therapeutics by 326.3% during the 2nd quarter. HighTower Advisors LLC now owns 132,353 shares of the company’s stock valued at $96,000 after acquiring an additional 101,308 shares in the last quarter. D.A. Davidson & CO. boosted its position in Vistagen Therapeutics by 27.3% during the 3rd quarter. D.A. Davidson & CO. now owns 105,000 shares of the company’s stock valued at $112,000 after acquiring an additional 22,500 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Vistagen Therapeutics by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 1,196,181 shares of the company’s stock valued at $868,000 after acquiring an additional 35,729 shares in the last quarter. 7.54% of the stock is currently owned by institutional investors.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Read More: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.